Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VY AADC

Drug Profile

VY AADC

Alternative Names: AAV-AADC; AAV-hAADC; AAV-hAADC-2; AAV-hAADC-gene-therapy - Voyager Therapeutics; AAV2-hAADC; AAV2-hAADC - Voyager Therapeutics; Aromatic-L-amino-acid-decarboxylase-gene-therapy; AV 201; GZ 404477; VY AADC01; VY AADC02

Latest Information Update: 31 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer National Institutes of Health (USA); University of California at San Francisco; Voyager Therapeutics
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Aromatic-L-amino-acid decarboxylase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 29 Jan 2019 Neurocrine Biosciences enter into an option agreement with Voyager Therapeutics to develop and commercialise VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia
  • 07 Jan 2019 Voyager plans a phase III RESTORE-2 trial for Parkinson's disease of similar design and size of RESTORE-1 trial in USA and worldwide in H1 of 2020
  • 07 Nov 2018 Long-term efficacy data from a phase Ib trial in Parkinson's disease released by Voyager Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top